BCI-838

an mGluR2-3 glutamate receptor antagonist

Also Known As:

MGS0210; bicyclo (3.1.0) hexane-2,6-dicarboxylic acid, 2-amino-3-((3,4-dichlorophenyl)metoxy)-6-fluoro-,6-heptyl ester,(IR,2R,3R, 5R6R)-)

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Bridged-Ring Compounds: 1
      - Bridged Bicyclo Compounds
        BCI-838: 3
Polycyclic Compounds: 6
- Bridged-Ring Compounds: 1
  - Bridged Bicyclo Compounds
    - BCI-838: 3

Experts

1.	Ahlers, Stephen T: 2 articles (01/2019 - 01/2018)
2.	De Gasperi, Rita: 2 articles (01/2019 - 01/2018)
3.	Elder, Gregory A: 2 articles (01/2019 - 01/2018)
4.	Gama Sosa, Miguel A: 2 articles (01/2019 - 01/2018)
5.	Gandy, Sam: 2 articles (01/2019 - 01/2018)
6.	McCarron, Richard M: 2 articles (01/2019 - 01/2018)
7.	Perez-Garcia, Georgina: 2 articles (01/2019 - 01/2018)
8.	Hof, Patrick R: 1 article (01/2019)
9.	Tschiffely, Anna E: 1 article (01/2019)
10.	Otero-Pagan, Alena: 1 article (01/2018)

Related Diseases

1.	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/01/2018 - "The aim of the current study was to determine whether BCI-838 could modify the anxiety response and reverse PTSD-related behaviors in rats exposed to a series of low-level blast exposures designed to mimic a human mTBI or subclinical blast exposure. " 01/01/2018 - "The safety profile of BCI-838 together with the therapeutic activities reported here, make BCI-838 a promising drug for the treatment of former battlefield Warfighters suffering from PTSD-related symptoms following blast-induced mTBI." 01/01/2018 - "BCI-838 treatment reversed PTSD-related behavioral traits improving anxiety and fear-related behaviors as well as long-term recognition memory. " 01/01/2018 - "PTSD-Related Behavioral Traits in a Rat Model of Blast-Induced mTBI Are Reversed by the mGluR2/3 Receptor Antagonist BCI-838." 01/01/2019 - "Findings that PTSD-related behavioral traits can be reversed by BCI-838, a group II metabotropic glutamate receptor antagonist offers insight into pathogenesis and possible treatment options for blast-related brain injury. "
2.	Treatment-Resistant Depressive Disorder 01/01/2018 - "In humans, BCI-838 is currently in clinical trials for refractory depression and suicidality. "
3.	Tauopathies 01/01/2023 - "These studies extend the potential utility of BCI-838 to neurodegenerative conditions that have tauopathy as their underlying basis. " 01/01/2023 - "Herein, we investigated effects of BCI-838 on PS19 male mice that express the tauopathy mutation MAPTP301S associated with human frontotemporal lobar degeneration (FTLD). " 01/01/2023 - "BCI-838, an orally active mGluR2/3 receptor antagonist pro-drug, rescues learning behavior deficits in the PS19 MAPTP301S mouse model of tauopathy."
4.	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/01/2023 - "Herein, we investigated effects of BCI-838 on PS19 male mice that express the tauopathy mutation MAPTP301S associated with human frontotemporal lobar degeneration (FTLD). "
5.	Brain Injuries (Brain Injury) 01/01/2019 - "Findings that PTSD-related behavioral traits can be reversed by BCI-838, a group II metabotropic glutamate receptor antagonist offers insight into pathogenesis and possible treatment options for blast-related brain injury. "

Related Drugs and Biologics

1.	metabotropic glutamate receptor 2
2.	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
3.	Prodrugs